These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32706964)

  • 21. Recent progress in the medicinal chemistry of gamma-secretase inhibitors.
    Olson RE; Albright CF
    Curr Top Med Chem; 2008; 8(1):17-33. PubMed ID: 18220929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine derivatives as γ-secretase modulators (Part 2).
    Takai T; Koike T; Nakamura M; Kajita Y; Yamashita T; Taya N; Tsukamoto T; Watanabe T; Murakami K; Igari T; Kamata M
    Bioorg Med Chem; 2016 Jul; 24(14):3192-206. PubMed ID: 27255179
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
    Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
    Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease.
    Bursavich MG; Harrison BA; Acharya R; Costa DE; Freeman EA; Hodgdon HE; Hrdlicka LA; Jin H; Kapadnis S; Moffit JS; Murphy DA; Nolan S; Patzke H; Tang C; Wen M; Koenig G; Blain JF; Burnett DA
    J Med Chem; 2017 Mar; 60(6):2383-2400. PubMed ID: 28230986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lead optimization of 4,4-biaryl piperidine amides as γ-secretase inhibitors.
    Close J; Heidebrecht R; Hendrix J; Li C; Munoz B; Surdi L; Kattar S; Tempest P; Moses P; Geng X; Hughes B; Smotrov N; Moxham C; Chapnick J; Kariv I; Nikov G; Burke JE; Deshmukh S; Jeliazkova-Mecheva V; Leach JK; Diaz D; Xu L; Yang Z; Kwei G; Moy L; Shah S; Tanga F; Kenefic C; Savage D; Shearman M; Ball RG; McNevin MJ; Markarewicz A; Miller T
    Bioorg Med Chem Lett; 2012 May; 22(9):3203-7. PubMed ID: 22483609
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Application of the bicyclo[1.1.1]pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor.
    Stepan AF; Subramanyam C; Efremov IV; Dutra JK; O'Sullivan TJ; DiRico KJ; McDonald WS; Won A; Dorff PH; Nolan CE; Becker SL; Pustilnik LR; Riddell DR; Kauffman GW; Kormos BL; Zhang L; Lu Y; Capetta SH; Green ME; Karki K; Sibley E; Atchison KP; Hallgren AJ; Oborski CE; Robshaw AE; Sneed B; O'Donnell CJ
    J Med Chem; 2012 Apr; 55(7):3414-24. PubMed ID: 22420884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis and structure-activity relationship of novel [3.3.1] bicyclic sulfonamide-pyrazoles as potent γ-secretase inhibitors.
    Aubele DL; Truong AP; Dressen DB; Probst GD; Bowers S; Mattson MN; Semko CM; Sun M; Garofalo AW; Konradi AW; Sham HL; Zmolek W; Wong K; Goldbach E; Quinn KP; Sauer JM; Brigham EF; Wallace W; Nguyen L; Bova MP; Hemphill SS; Basi G
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5791-4. PubMed ID: 21885276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fluorinated benzophenone derivatives: balanced multipotent agents for Alzheimer's disease.
    Belluti F; De Simone A; Tarozzi A; Bartolini M; Djemil A; Bisi A; Gobbi S; Montanari S; Cavalli A; Andrisano V; Bottegoni G; Rampa A
    Eur J Med Chem; 2014 May; 78():157-66. PubMed ID: 24681980
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
    D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
    Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent γ-secretase inhibitors/modulators interact with amyloid-β fibrils but do not inhibit fibrillation: a high-resolution NMR study.
    Yesuvadian R; Krishnamoorthy J; Ramamoorthy A; Bhunia A
    Biochem Biophys Res Commun; 2014 May; 447(4):590-5. PubMed ID: 24747079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel orally active morpholine N-arylsulfonamides gamma-secretase inhibitors with low CYP 3A4 liability.
    Josien H; Bara T; Rajagopalan M; Clader JW; Greenlee WJ; Favreau L; Hyde LA; Nomeir AA; Parker EM; Song L; Zhang L; Zhang Q
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6032-7. PubMed ID: 19800786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suspected limited efficacy of γ-secretase modulators.
    Kakuda N; Akazawa K; Hatsuta H; Murayama S; Ihara Y;
    Neurobiol Aging; 2013 Apr; 34(4):1101-4. PubMed ID: 23058852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gamma Secretase Modulators: New Alzheimer's Drugs on the Horizon?
    Bursavich MG; Harrison BA; Blain JF
    J Med Chem; 2016 Aug; 59(16):7389-409. PubMed ID: 27007185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploring the chemical space of gamma-secretase modulators.
    Zettl H; Weggen S; Schneider P; Schneider G
    Trends Pharmacol Sci; 2010 Sep; 31(9):402-10. PubMed ID: 20591508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amelioration of cognitive deficits in plaque-bearing Alzheimer's disease model mice through selective reduction of nascent soluble Aβ42 without affecting other Aβ pools.
    Mitani Y; Yarimizu J; Akashiba H; Shitaka Y; Ni K; Matsuoka N
    J Neurochem; 2013 May; 125(3):465-72. PubMed ID: 23240999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of bicyclic heterocycles as potent γ-secretase modulators.
    Oehlrich D; Rombouts FJ; Berthelot D; Bischoff FP; De Cleyn MA; Jaroskova L; Macdonald G; Mercken M; Surkyn M; Trabanco AA; Tresadern G; Van Brandt S; Velter AI; Wu T; Gijsen HJ
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4794-800. PubMed ID: 23890837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis, and structure-activity relationship studies of N-arylsulfonyl morpholines as γ-secretase inhibitors.
    Li H; Xu R; Cole D; Clader JW; Greenlee WJ; Nomeir AA; Song L; Zhang L
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6606-9. PubMed ID: 20933414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of a series of efficient, centrally efficacious BACE1 inhibitors through structure-based drug design.
    Butler CR; Brodney MA; Beck EM; Barreiro G; Nolan CE; Pan F; Vajdos F; Parris K; Varghese AH; Helal CJ; Lira R; Doran SD; Riddell DR; Buzon LM; Dutra JK; Martinez-Alsina LA; Ogilvie K; Murray JC; Young JM; Atchison K; Robshaw A; Gonzales C; Wang J; Zhang Y; O'Neill BT
    J Med Chem; 2015 Mar; 58(6):2678-702. PubMed ID: 25695670
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative pharmacokinetic/pharmacodynamic analyses suggest that the 129/SVE mouse is a suitable preclinical pharmacology model for identifying small-molecule γ-secretase inhibitors.
    Lu Y; Zhang L; Nolan CE; Becker SL; Atchison K; Robshaw AE; Pustilnik LR; Osgood SM; Miller EH; Stepan AF; Subramanyam C; Efremov I; Hallgren AJ; Riddell D
    J Pharmacol Exp Ther; 2011 Dec; 339(3):922-34. PubMed ID: 21930801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.